Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2007 1
2008 3
2009 3
2010 1
2011 2
2012 4
2013 3
2014 5
2015 3
2016 1
2017 2
2018 1
2019 2
2020 1
2021 7
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
PD-L1 expression in triple-negative breast cancer.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. Mittendorf EA, et al. Among authors: akcakanat a. Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10. Cancer Immunol Res. 2014. PMID: 24764583 Free PMC article.
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Zhao M, et al. Among authors: akcakanat a. NPJ Breast Cancer. 2023 Aug 11;9(1):66. doi: 10.1038/s41523-023-00573-8. NPJ Breast Cancer. 2023. PMID: 37567892 Free PMC article.
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF; NCI PDXNet Consortium; Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Sun H, et al. Nat Commun. 2021 Aug 24;12(1):5086. doi: 10.1038/s41467-021-25177-3. Nat Commun. 2021. PMID: 34429404 Free PMC article.
MK-2206 window of opportunity study in breast cancer.
Akcakanat A, Meric-Bernstam F. Akcakanat A, et al. Ann Transl Med. 2018 Nov;6(Suppl 1):S57. doi: 10.21037/atm.2018.10.32. Ann Transl Med. 2018. PMID: 30613632 Free PMC article. No abstract available.
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Hassan B, et al. Among authors: akcakanat a. Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Surg Oncol Clin N Am. 2013. PMID: 24012393 Free PMC article. Review.
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Woo XY, et al. Nat Genet. 2021 Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Nat Genet. 2021. PMID: 33414553 Free PMC article.
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. DiPeri TP, et al. Among authors: akcakanat a. Cancer Discov. 2024 May 1;14(5):828-845. doi: 10.1158/2159-8290.CD-23-0838. Cancer Discov. 2024. PMID: 38358339 Clinical Trial.
Targeting translation initiation in breast cancer.
Akcakanat A, Hong DS, Meric-Bernstam F. Akcakanat A, et al. Translation (Austin). 2014 Apr 29;2(1):e28968. doi: 10.4161/trla.28968. eCollection 2014. Translation (Austin). 2014. PMID: 26779407 Free PMC article. Review.
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Akcakanat A, et al. Clin Cancer Res. 2021 Jun 1;27(11):3243-3252. doi: 10.1158/1078-0432.CCR-20-4048. Epub 2021 Mar 29. Clin Cancer Res. 2021. PMID: 33782032 Free PMC article.
47 results